血清CA153 hMAM CXCL8联合诊断乳腺癌的应用价值

doi:10.3969/j.issn.1006-6233.2025.03.014

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1332 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 研究血清CA153、hMAM、CXCL8联合诊断乳腺癌的应用价值。方法: 选择2022年1月至2023年12月我院收治的乳腺癌患者80例纳入乳腺癌组,选择同期我院收治的良性乳腺肿瘤患者80例纳入良性组,选择同期于我院进行健康体检的健康人80例纳入对照组。采集乳腺癌组、良性组入院次日,对照组体检日清晨空腹静脉血,提取血清,以电化学发光法检测CA153,以ELISA法检测hMAM、CXCL8,观察三组血清CA153、hMAM、CXCL8水平;乳腺癌组不同TNM分期患者血清CA153、hMAM、CXCL8水平。以Pearson相关分乳腺癌组血清CA153、hMAM、CXCL8水平与TNM分期的相关性。以受试者工作特征(ROC)曲线评价CA153、hMAM、CXCL8联合诊断乳腺癌的效能。结果: 乳腺癌组血清CA153、hMAM、CXCL8均高于良性组、对照组,差异有统计学意义(P<0.05);良性组血清CA153、hMAM、CXCL8均高于对照组,差异有统计学意义(P<0.05)。I期患者血清CA153、hMAM、CXCL8均低于Ⅱ期、Ⅲ期患者,Ⅱ期患者血清CA153、hMAM、CXCL8均低于Ⅲ期患者,差异有统计学意义(P<0.05)。经Pearson相关分析,血清CA153、hMAM、CXCL8水平与TNM分期正相关(r=0.857、1.137、1.968,P<0.05)。经ROC曲线分析,血清CA153、hMAM、CXCL8联合对乳腺癌的的诊断效能高于三者单独诊断。结论: 乳腺癌患者血清CA153、hMAM、CXCL8水平与其TNM分期正相关,血清CA153、hMAM、CXCL8联合对乳腺癌具有较高的诊断价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：乳腺癌, CA153, hMAM, CXCL8, 诊断价值

Abstract：Objective: To study the clinical value of serum carbohydrate antigen 153 (CA153), human mammaglobin (hMAM) and C-X-C motif ligand 8 (CXCL8) in the diagnosis of breast cancer (BC). Methods: Eighty patients with BC (BC group), 80 patients with benign breast tumor (BBT group), and 80 patients with healthy physical examination (control group) who visited our hospital from January 2022 to December 2023 were enrolled in the study. Fasting venous blood was collected from the patients of BC group and BBT group on the next day of admission, and the patients of the control group on the morning of physical examination. Serum was extracted, CA153, and hMAM and CXCL8 were respectively detected by electrochemiluminescence and enzyme-linked immunosorbent assay (ELISA). The serum levels of CA153, hMAM and CXCL8 of the patients in the three groups were counted. Pearson correlation was used to analyze the correlation between serum CA153, hMAM, CXCL8 levels and tumor-node-metastasis (TNM) stage in BC group. The efficacy of CA153, hMAM and CXCL8 in the diagnosis of BC was evaluated by receiver operating characteristic (ROC) curve. Results: The serum CA153, hMAM and CXCL8 in BC group were significantly higher than those in BBT group and control group (P<0.05), and which in BBT group were significantly higher than those of the control group (P<0.05). The serum CA153, hMAM and CXCL8 in patients with stage I were significantly lower than those in patients with stages II, III, and which in patients with stage II were significantly lower than those of patients with stage III (P<0.05). The serum levels of CA153, hMAM and CXCL8 were positively correlated with TNM stage by Pearson correlation analysis (r=0.857, 1.137, 1.968, P<0.05). According to ROC curve analysis, the combined efficacy of serum CA153, hMAM and CXCL8 in the diagnosis of BC was significantly higher than that of the three alone. Conclusion: The levels of serum CA153, hMAM and CXCL8 in patients with BC are positively correlated with TNM stage, and the combination of serum CA153, hMAM and CXCL8 has high diagnostic value for BC.

Key words： Breast cancer CA153 hMAM CXCL8 Diagnostic value

基金资助:湖北省卫生健康委员会科研项目,(编号:WJ2021M001)

通讯作者: 宁晓洁

引用本文:

郑莉, 祝孔俊, 龚爱云, 张静, 刘梦婷, 宁晓洁. 血清CA153 hMAM CXCL8联合诊断乳腺癌的应用价值[J]. 河北医学, 2025, 31(3): 431-434.
ZHENG Li, ZHU Kongjun, GONG Aiyun, et al. Clinical Value of Serum CA153 hMAM and CXCL8 in the Diagnosis of Breast Cancer. HeBei Med, 2025, 31(3): 431-434.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.03.014 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I3/431

[1] Tarighati E,Keivan H,Mahani H.A review of prognostic and predictive biomarkers in breast cancer[J].Clin Exp Med,2023,23(1):1-16.
[2] Mishra A,Suman KH,Nair N,et al.An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer[J].Mol Biol Rep,2021,48(9):6551-6561.
[3] 中国抗癌协会乳腺癌专业委员会.中国晚期乳腺癌临床诊疗专家共识( 2018版)[J].中华肿瘤杂志,2018,40(9):703-713.
[4] 中华预防医学会妇女保健分会乳腺保健与乳腺疾病防治学.乳腺纤维腺瘤诊治专家共识[J].中国实用外科杂志,2016,36(7):752-754.
[5] Fan Y,Chen X,Li H.Clinical value of serum biomarkers CA153,CEA,and white blood cells in predicting sentinel lymph node metastasis of breast cancer[J].Int Clin Exp Pathol,2020,13(11):2889-2894.
[6] Li J,Liu L,Feng Z,et al.Tumor markers CA15-3,CA125,CEA and breast cancer survival by molecular subtype:a cohort study[J].Breast Cancer,2020,27(4):621-630.
[7] Bel'skaya LV,Sarf EA,Loginova AI,et al.Potential diagnostic value of salivary tumor markers in breast,lung and ovarian cancer:a preliminary study[J].Curr Issues Mol Biol,2023,45(6):5084-5098.
[8] Mi J,Zhang H,Cao W,et al.FTO,PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer[J].Medicine (Baltimore),2023,102(42):35361.
[9] Ghasemi-Dehkordi P,Doosti A,Jami MS.The functions of azurin of Pseudomonas aeruginosa and human mammaglobin-A on proapoptotic and cell cycle regulatory genes expression in the MCF-7 breast cancer cell line[J].Saudi Biol Sci,2020,27(9):2308-2317.
[10] Milosevic B,Stojanovic B,Cvetkovic A,et al.The enigma of mammaglobin:redefining the biomarker paradigm in breast carcinoma[J].Int Mol Sci,2023,24(17):13407.
[11] Zhang Z,Wang H,Jin Y,et al.Potential of blood exosomal ENAH,SEPT9,EGF,MMP-9 and CXCL8 for the early screening of breast cancer[J].Oncol Lett,2022,24(6):460.
[12] Seale KN,Tkaczuk KHR.Circulating biomarkers in breast cancer[J].Clin Breast Cancer,2022,22(3):319-331.
[13] Bonacho T,Rodrigues F,Liberal J.Immunohistochemistry for diagnosis and prognosis of breast cancer:a review[J].Biotech Histochem,2020,95(2):71-91.
[14] Stepien S,Smycz-Kubanska M,Kruszniewska-Rajs C,et al.Clinical significance of the CXCL8/CXCR1/R2 signalling axis in patients with invasive breast cancer[J].Oncol Lett,2024,27(6):260.